Amarin announced that the Company’s Board of Directors has appointed Aaron Berg, currently Amarin’s Executive Vice President and President of the U.S. Business, as Interim President and Chief Executive Officer. In addition, the board has appointed Oliver O’Connor as a new independent Director of the company. Both appointments are effective immediately. Berg joined Amarin in November 2012 and has more than 25 years of biopharmaceutical industry experience.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on AMRN:
- Amarin Names Aaron Berg Interim President & Chief Executive Officer and Adds Oliver O’Connor to Company’s Board of Directors
- Amarin announces VAZKEPA approved by Israel’s MOH
- Amarin Announces VAZKEPA® (Icosapent Ethyl) Approved by Israel’s Ministry of Health
- Amarin says board ‘ready’ to unlock true potential of VASCEPA/VAZKEPA
- Amarin Announces Board Departures
